Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust
Kadcyla will be used to treat the patients who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. Kadcyla
Padcev, a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4 protein, has secured approval under the FDA’s Accelerated Approval Program based on tumour response rate. Nectin-4, which
As published in The New England Journal of Medicine (NEJM), results from the BEACON CRC trial showed improvements in overall survival (OS) and objective response rates (ORR) for
The randomized controlled trial will enroll approximately 30 patients with Relapsing MS for eight weeks treatment with digital therapy and evaluate dosing, patient use, engagement, and other clinical
The status has been provided to DCR-A1AT based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). A1AT deficiency
Upon completion of the merger, the merged company would operate under the name Tarveda Therapeutics, Inc. and trade on the Nasdaq Stock Market LLC under the ticker symbol
HemaCare has expertise in the customisation of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. HemaCare provides a range of human
TED is a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement that can
The company has unveiled the topline results from its global phase 111 Luster-1 and Luster-2 studies evaluating the efficacy and safety of the investigational oral, once-daily, DP2 receptor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.